In 2009 Mikhail Blagosklonny, who hails from Russia, became part of the Roswell Park Cancer Institute as a professor of oncology with a focus on TOR research to develop a solution to solve the puzzle of cancer.
Research into TOR, which stands for ‘Target of Rapamycin’ and is sometimes called the ‘Engine-of-aging Enzyme,’ is being studied by many others as well. View Mikhail’s profile in LinkedIn
In basic terms; the idea is that a lot of serious illnesses including cancer occur with much greater frequency in people as they get older. Therefore, if an anti-aging solution can be found, or at least partially realized, then the incidences of cancer and other diseases could be dramatically reduced.
There is also the fact that another facet of the overall goal of this approach is that the preventive and treatment procedures will be less painful, time consuming and less expensive.
Mikhail Blagosklonny, who once worked as a senior scientist for the Ordway Research Institute, is not some radical maverick spouting useless rhetoric. His has a highly trained and organized mind and is very devoted to scientific method as shown in this article here on the U.S Government Website: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615154/
Being rather prolific despite his busy schedule; Mikhail Blagosklonny is also the author of over 300 articles in various publications. He is a sought after editor currently serving as the Associate Editor of Cancer Biology and Therapy, International Journal for Cancer, and the American Journal of Pathology. He is the Founder, Editor and Editor in Chief of Cell Cycle and also an associate editor of the prestigious Journal of Cancer Biology & Therapy.
Read more: http://www.aging-us.com/article/100591/text
Mikhail Blagosklonny is the current Professor of Oncology at the Institute of Roswell Park of Cancer located in Buffalo. The institute is one of the few comprehensive cancer treatment institutions located in New York. Before being appointed to the school, he was a teacher at the New York Medical College. He was also a researcher at the Ordway Research Institute located in Albany. Before coming to the United States, Dr. Blagosklonny did his medical education at the Pavlov Medical University located in St. Petersburg in Russia. He later advanced his education and completed a Ph.D. in experimentation medicine within the same institution.
Mikhail has made several contributions to the field of oncology. He has focused his experimental skills on LinkedIn and intellect to look for treatment in aging and cancer that offer long-term solutions. His concern has been to find a cure that can kill infected cancer cells. The treatment should not interfere the healthier cells during the entire process. He has researched to understand how the anti-aging medication functions. He wants to create an effective solution to the problem of getting old.
Blagosklonny is popular for the formation of a hypothesis surrounding TOR signal in cancer and aging. He proposed the use of Rapamycin enzyme, a traditional enzyme and drug, to treat life extension. He has researched deeply on the use of Rapamycin. His level of research has seen him become one of the world’s most passionate researcher on ImpactJournals.com in Rapamycin and its anti-aging results. Blagosklonny is the chief editor of several publications. He has authored Oncotarget, Cell Cycle, Aging and other publications. He is also an associate editor of a journal known as Cancer Therapy and Biology. He is a member of the editorial team that handles Cell Differentiation and Death.
Mikhail is popular for the aging hyperfunction theory at https://en.wikipedia.org/wiki/Mikhail_Blagosklonny. He has focused on writing about chemotherapeutic engineering. Mikhail’s interest in cancer and oncology has seen him believe that there is a treatment for cancer. He has written over 300 research articles that focus on the issue. He has grown to become one of the biggest Oncology Researchers known in the world today. He has shown a deep love for humanity and a strong vision to create a world that is disease-free.